1. McCluskey P, Powell RJ. The eye in systemic inflammatory diseases. Lancet. 2004; 364:2125–33.
Article
2. Hamideh F, Prete PE. Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum. 2001; 30:217–41.
Article
3. Foster CS. Ocular manifestations of the potentially lethal rheumatologic and vasculitic disorders. J Fr Ophtalmol. 2013; 36:526–32.
Article
4. Hunter RS, Skondra D, Papaliodis G, Sobrin L. Role of OCT in the diagnosis and management of macular edema from uveitis. Semin Ophthalmol. 2012; 27:236–41.
Article
5. Kim NK, Park MY, Lee JH, Lee DH, Yoon BY. Uveitis and Rheumatic diseases in a community based practice - Korean population. J Rheum Dis. 2011; 18:276–82.
Article
6. Farris RL, Stuchell RN, Nisengard R. Sjogren's syndrome and keratoconjunctivitis sicca. Cornea. 1991; 10:207–9.
Article
7. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5:75–92.
8. Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am. 2007; 33:835–54.
Article
9. Akpek EK, Thorne JE, Qazi FA, Do DV, Jabs DA. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004; 111:501–6.
Article
10. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. 1984; 91:1253–63.
11. Rothova A, van Veenedaal WG, Linssen A, Glasius E, Kijlstra A, de Jong PT. Clinical features of acute anterior uveitis. Am J Ophthalmol. 1987; 103:137–45.
Article
12. Poole TR, Graham EM. Ocular manifestations of rheumatologic disorders. Curr Opin Ophthalmol. 1999; 10:458–63.
Article
13. Giordano N, D'Ettorre M, Biasi G, Fioravanti A, Moretti L, Marcolongo R. Retinal vasculitis in rheumatoid arthritis: an angiographic study. Clin Exp Rheumatol. 1990; 8:121–5.
14. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64:625–39.
Article
15. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991; 34:1218–27.
Article
16. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008; 67:955–9.
Article
17. Rosenbaum JT. Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am. 1992; 18:143–51.
Article
18. Tay-Kearney ML, Schwam BL, Lowder C, Dunn JP, Meisler DM, Vitale S, et al. Clinical features and associated systemic diseases of HLA-B27 uveitis. Am J Ophthalmol. 1996; 121:47–56.
Article
19. Pavlidis NA, Karsh J, Moutsopoulos HM. The clinical picture of primary Sjögren's syndrome: a retrospective study. J Rheumatol. 1982; 9:685–90.
20. Friedlaender MH. Ocular manifestations of Sjögren's syndrome: keratoconjunctivitis sicca. Rheum Dis Clin North Am. 1992; 18:591–608.
Article
21. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5:163–78.
22. Morton SJ, Powell RJ. Management of systemic lupus erythematosus (SLE). Clin Exp Allergy. 2001; 31:686–93.
Article
23. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behç et disease: an analysis of 880 patients. Am J Ophthalmol. 2004; 138:373–80.
24. Yu HG, Kim MJ, Oh FS. Fluorescein angiography and visual acuity in active uveitis with Behç et disease. Ocul Immunol Inflamm. 2009; 17:41–6.
25. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behç et disease. Am J Ophthalmol. 2008; 146:845–50.e1.
26. Nowinski TS. Ocular manifestations of sarcoidosis. Curr Opin Ophthalmol. 1998; 9:80–4.
Article
27. Usui Y, Kaiser ED, See RF, Rao NA, Sharma OP. Update of ocular manifestations in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002; 19:167–75.
28. Nowinski T, Flanagan J, Ruchman M. Lacrimal gland en-largement in familial sarcoidosis. Ophthalmology. 1983; 90:909–13.
Article
29. Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012; 2012; 290898.
Article
30. Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007; 46:1757–62.
Article
31. Jabs DA, Fine SL, Hochberg MC, Newman SA, Heiner GG, Stevens MB. Severe retinal vaso-occlusive disease in systemic lupus erythematous. Arch Ophthalmol. 1986; 104:558–63.
32. Peponis V, Kyttaris VC, Tyradellis C, Vergados I, Sitaras NM. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus. 2006; 15:3–12.
Article
33. Peponis V, Kyttaris VC, Chalkiadakis SE, Bonovas S, Sitaras NM. Ocular side effects of antirheumatic medications: what a rheumatologist should know. Lupus. 2010; 19:675–82.
34. Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet. 1959; 2:478–80.
Article
35. Lee AG. Hydroxychloroquine screening. Br J Ophthalmol. 2005; 89:521–2.
Article
36. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011; 118:415–22.
Article
37. West SK, Valmadrid CT. Epidemiology of risk factors for age-related cataract. Surv Ophthalmol. 1995; 39:323–34.
38. Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res. 2009; 88:752–9.
Article